Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Haemopoietic Growth Factors

Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study

Bone Marrow Transplantation volume 27, pages 261–268 (2001)Cite this article

Abstract

Thrombocytopenia following myelotoxic therapy is a common problem and when severe (<20 000/μl) can lead to severe morbidity and mortality. Thrombopoietin (TPO) is a naturally occurring glycosylated peptide which stimulates the differentiation of bone marrow stem cells into megakaryocyte progenitor cells, induces the expression of megakaryocyte differentiation markers, promotes megakaryocyte proliferation, polyploidization and, ultimately, the formation of increased numbers of platelets in the circulation. TPO has now been produced by recombinant technology and has entered clinical trials. This open label phase I study was designed to determine the safety, tolerance and pharmacokinetics of recombinant thrombopoietin (rhTPO) when administered to patients after undergoing high-dose chemotherapy followed by autologous bone marrow transplantation. rhTPO was administered intravenously by bolus injection at doses ranging from 0.3 to 4.8 μg/kg/day every 3 days to 30 patients and 0.6 μg/kg daily to three patients. rhTPO was begun the day after marrow infusion and continued until platelet recovery to <20 000/μl. G-CSF was concomitantly administered to promote myeloid recovery. Serious adverse events or neutralizing antibodies to rhTPO were not observed during the study. Median platelet recovery after ABMT was 19 days (range, 11–41). Neither the dose nor the schedule of rhTPO appeared to have any impact upon the time course of platelet recovery. In this phase I study, rhTPO was found to be well tolerated without the development of neutralizing antibodies and without compromising neutrophil recovery. Platelet recovery was similar for all doses studied warranting further evaluation in phase II and III trials designed to test for platelet recovery efficacy. Bone Marrow Transplantation (2001) 27, 261–268.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Fetscher S, Mertelsmann R . Supportive care in hematological malignancies: hematopoietic growth factors, infections, transfusion therapy Curr Opin Hematol 1999 6: 262–273

    Article  CAS  PubMed  Google Scholar 

  2. Webb IJ, Anderson KC . Risks, costs, and alternatives to platelet transfusions Leuk Lymphoma 1999 34: 71–84

    Article  CAS  PubMed  Google Scholar 

  3. Gmur J, Burger J, Schanz U et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia Lancet 1991 338: 1223–1226

    Article  CAS  PubMed  Google Scholar 

  4. Heckman KD, Weiner GJ, Davis CS et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10 000/microl versus 20 000/microl J Clin Oncol 1997 15: 1143–1149

    Article  CAS  PubMed  Google Scholar 

  5. Rebulla P, Finazzi G, Marangoni F et al. A multicenter randomized study of the threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto New Engl J Med 1997 337: 1870–1875

    Article  CAS  PubMed  Google Scholar 

  6. Wandt H, Frank M, Ehninger G et al. Safety and cost effectiveness of a 10 × 109/l trigger for prophylactic platelet transfusions compared with the traditional 20 × 109/l trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia Blood 1998 91: 3601–3606

    CAS  PubMed  Google Scholar 

  7. Blay JY, Le Cesne A, Mermet C et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy Blood 1998 92: 405–410

    CAS  PubMed  Google Scholar 

  8. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy Lancet 1992 339: 640–644

    Article  CAS  PubMed  Google Scholar 

  9. Nash R, Gooley T, Davis C, Appelbaum F . The problem of thrombocytopenia after hematopoietic stem cell transplantation Stem Cells 1996 14: (Suppl. 1) 261–273

    Article  PubMed  Google Scholar 

  10. Hassan H, Zander AR . Thrombocytopenia after high-dose chemotherapy and autologous stem cell transplantation: an unresolved problem and possible approaches to resolve it J Hematother 1996 5: 407–414

    Article  CAS  PubMed  Google Scholar 

  11. Bernstein S, Nademanee A, Vose J et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation Blood 1998 91: 3509–3517

    CAS  PubMed  Google Scholar 

  12. Smith B, Jones R, Piantidosi S et al. Autologous bone marrow transplantation (ABMT) using 4hydroperoxycyclophosphamide (4HC) purging for acute myeloid leukemia beyond first remission: a ten year experience Blood 1998 92: (Suppl. 1) 323A

    Google Scholar 

  13. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells J Clin Oncol 1995 13: 2547–2555

    Article  CAS  PubMed  Google Scholar 

  14. Pecora AL, Preti RA, Gleim GW et al. CD34+CD33− cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients J Clin Oncol 1998 16: 2093–2104

    Article  CAS  PubMed  Google Scholar 

  15. Brown RA, Adkins D, Goodnough LT et al. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies J Clin Oncol 1997 15: 3067–3074

    Article  CAS  PubMed  Google Scholar 

  16. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients Blood 1995 85: 588–596

    CAS  PubMed  Google Scholar 

  17. Alexander WS, Begley CG . Thrombopoietin in vitro and in vivo Cytokines Cell Mol Ther 1998 4: 25–34

    CAS  PubMed  Google Scholar 

  18. Baatout S . Thrombopoietin. A review Haemostasis 1997 27: 1–8

    CAS  PubMed  Google Scholar 

  19. Cohen-Solal K, Debili N, Vainchenker W, Wendling F . Thrombopoietin (Mpl ligand) and the regulation of platelet production Eur Cytokine Netw 1997 8: 311–314

    CAS  PubMed  Google Scholar 

  20. Kaushansky K . Thrombopoietin and the hematopoietic stem cell Blood 1998 92: 1–3

    CAS  PubMed  Google Scholar 

  21. Brereton ML, Adams JA, Briggs M, Liu Yin JA . The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryopoiesis in patients with aplastic anaemia Br J Haematol 1999 104: 119–126

    Article  CAS  PubMed  Google Scholar 

  22. Neelis KJ, Qingliang L, Thomas GR et al. Prevention of thrombocytopenia by thrombopoietin in myelosuppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion Blood 1997 90: 58–63

    CAS  PubMed  Google Scholar 

  23. Harker LA . Physiology and clinical applications of platelet growth factors Curr Opin Hematol 1999 6: 127–134

    Article  CAS  PubMed  Google Scholar 

  24. Harker LA, Marzec UM, Novembre F et al. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor Blood 1998 91: 4427–4433

    CAS  PubMed  Google Scholar 

  25. Basser RL, Rasko JE, Clarke K et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer (published erratum appears in Blood 1997; 90: 2513) Blood 1997 89: 3118–3128

    CAS  PubMed  Google Scholar 

  26. Basser RL, Rasko JE, Clarke K et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer Lancet 1996 348: 1279–1281

    Article  CAS  PubMed  Google Scholar 

  27. Abraham R, Basser RL . Megakaryocyte growth and development factor: a review of early clinical studies Oncologist 1997 2: 311–318

    CAS  PubMed  Google Scholar 

  28. O'Malley CJ, Rasko JE, Basser RL et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation Blood 1996 88: 3288–3298

    CAS  PubMed  Google Scholar 

  29. Fanucchi M, Glaspy J, Crawford J et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer (see comments) New Engl J Med 1997 336: 404–409

    Article  CAS  PubMed  Google Scholar 

  30. Joncheere A . A distribution-free k-sample test against ordered alternatives Biometrika 1954 41: 133–145

    Article  Google Scholar 

  31. Terpstra T . The asymptotic normality and consistency of Kendall's test against trend when ties are present in one ranking Indagationes Mathamaticae 1952 14: 327–333

    Article  Google Scholar 

  32. Hollander M, Wolfe DA . Nonparametric Statistical Methods Wiley: New York 1973

  33. Lowe J, Peterson M, Ramsey D et al. A novel bioassay for analysis of neutralizing anti-thrombopoietin antibodies Blood 1996 88: (Suppl. 1) A1397

    Google Scholar 

  34. Neelis KJ, Hartong SC, Egeland T et al. The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys Blood 1997 90: 2565–2573

    CAS  PubMed  Google Scholar 

  35. Beveridge R, Schuster M, Waller E et al. Randomized, double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor (Peg-MGDF) in breast cancer patients (pts) following autologous bone marrow transplantation (ABMT) Blood 1997 90:: (Suppl. 1) 580a

    Google Scholar 

  36. Shimazaki C, Inaba T, Uchiyama H et al. Serum thrombopoietin levels in patients undergoing autologous peripheral blood stem cell transplantation Bone Marrow Transplant 1997 19: 771–775.

    Article  CAS  PubMed  Google Scholar 

  37. Porcelijn L, Folman CC, Bossers B et al. The diagnostic value of thrombopoietin level measurements in thrombocytopenia Thromb Haemost 1998 79: 1101–1105

    Article  CAS  PubMed  Google Scholar 

  38. Cerutti A, Custodi P, Duranti M et al. Thrombopoietin levels in patients with primary and reactive thrombocytosis Br J Haematol 1997 99: 281–284

    Article  CAS  PubMed  Google Scholar 

  39. Tepler I, Elias L, Smith JW II et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy Blood 1996 87: 3607–3614

    CAS  PubMed  Google Scholar 

  40. Vredenburgh JJ, Hussein A, Fisher D et al. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer Biol Blood Marrow Transplant 1998 4: 134–141

    Article  CAS  PubMed  Google Scholar 

  41. Vadhan-Raj S, Murray LJ, Bueso-Ramos C et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer Ann Intern Med 1997 126: 673–681

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vanderbilt University, Nashville, TN, USA

    SN Wolff, JP Greer, R Stein & S Goodman

  2. University of Louisville, Louisville, KY, USA

    R Herzig

  3. University of West Virginia, Morgantown, WV, USA

    J Lynch & SG Ericson

  4. Genentech, Inc., South San Francisco, CA, USA

    MC Benyunes, M Ashby & DVJones Jr

  5. Baylor University Medical Center, Dallas, TX, USA

    J Fay

Authors
  1. SN Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Herzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. SG Ericson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. JP Greer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Goodman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. MC Benyunes
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Ashby
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. DVJones Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Fay
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wolff, S., Herzig, R., Lynch, J. et al. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study. Bone Marrow Transplant 27, 261–268 (2001). https://doi.org/10.1038/sj.bmt.1702772

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702772

Keywords

This article is cited by

Search

Advanced search

Quick links